Alberta Diabetes Institute to Study Use of Anti-Obesity Drug in Alström and Bardet-Biedl Patients
mcmurryjulie / Pixabay

Alberta Diabetes Institute to Study Use of Anti-Obesity Drug in Alström and Bardet-Biedl Patients

According to a publication from EurekAlert, a clinical trial of setmelanotide, an experimental anti-obesity drug, is set to begin soon at the Alberta Diabetes Institute (of the University of Alberta).…

Continue Reading Alberta Diabetes Institute to Study Use of Anti-Obesity Drug in Alström and Bardet-Biedl Patients
Possible Treatment for Homozygous Familial Hypercholesterolemia Earns Orphan Drug Designation
katicaj / Pixabay

Possible Treatment for Homozygous Familial Hypercholesterolemia Earns Orphan Drug Designation

According to a story from bloomberg.com, the drug development company Arrowhead Pharmaceuticals, Inc. recently announced that its experimental product candidate AR0-ANG3 has earned Orphan Drug designation from the US Food…

Continue Reading Possible Treatment for Homozygous Familial Hypercholesterolemia Earns Orphan Drug Designation
Antibodies: The Key to Fighting Sickle Cell Anemia? Approval Could be Just Months Away
kalhh / Pixabay

Antibodies: The Key to Fighting Sickle Cell Anemia? Approval Could be Just Months Away

According to a story from PMLive, the US Food and Drug Administration (FDA) has recently begun the priority review process for a new potential therapy from pharmaceutical behemoth Novartis. This…

Continue Reading Antibodies: The Key to Fighting Sickle Cell Anemia? Approval Could be Just Months Away

Huntsman Lab Research Team Discovers that Selinexor May Benefit Myelofibrosis Patients Who have No Other Curative Options

  Myelofibrosis (MF) comes under the heading of rare cancer. A recent article in Newswise, University of Utah, describes the disease as the failure of bone marrow to produce normal…

Continue Reading Huntsman Lab Research Team Discovers that Selinexor May Benefit Myelofibrosis Patients Who have No Other Curative Options
Close Menu